EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

The Dual Role of SLC7A11 in Colorectal Cancer Ferroptosis: From Molecular Mechanisms to Therapeutic Opportunities

Siyu Hu iD, Yuting Wang, Guangyu Tian, Zhiyuan Qiu

OncoTargets and Therapy · 2026-01 · Volume 19 · 1-12

DOI: 10.2147/ott.s569536 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift OncoTargets and Therapy, 2026-01. Verfasst von Siyu Hu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, People's Hospital Affiliated to Jiangsu University, Zhenjiang, Jiangsu, 212000, People's Republic of China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) ranks as the third most prevalent malignancy globally based on recent epidemiological studies. In China, the rising incidence and mortality rates of CRC have underscored the importance of elucidating its pathogenic mechanisms, which remain major focus in current biomedical research. Ferroptosis, a regulated cell death process driven by iron-dependent lipid peroxidation, is closely associated with disruptions in iron homeostasis, lipid metabolism, and amino acid metabolism. This unique iron-catalysed death process plays a crucial role in both tumor initiation and malignant progression by disturbing cellular redox imbalance. The cystine/glutamate antiporter SLC7A11 (also known as xCT) has been identified as a central regulator of ferroptosis susceptibility. The tumor suppressor p53 and its associated microRNAs modulate ferroptotic responses through regulation of SLC7A11 expression, forming a critical axis in oncogenic transformation and metastasis. However, the precise role of SLC7A11 in CRC-particularly its context-dependent dual functions as both a tumor promoter and a therapeutic vulnerability-remains a critical unanswered question. This review aims to systematically summarize current advances in understanding the multiple roles of SLC7A11 in CRC-related ferroptosis pathways and to evaluate emerging therapeutic strategies targeting this axis. Importantly, we also underscore the existing knowledge gaps and outline future research directions essential for leveraging this unique molecular pathway to improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

SLC7A11colorectal cancerferroptosis

Autor:innen und Institutionen

  • Department of Oncology, People's Hospital Affiliated to Jiangsu University, Zhenjiang, Jiangsu, 212000, People's Republic of China.
  • Department of Oncology, Yangzhou University Jiangdu People's Hospital, Yangzhou, Jiangsu, 225000, People's Republic of China.

ORCID-Profile: Siyu Hu

Zitieren

APA

Hu, S., Wang, Y., Tian, G., & Qiu, Z. (2026). The Dual Role of SLC7A11 in Colorectal Cancer Ferroptosis: From Molecular Mechanisms to Therapeutic Opportunities. OncoTargets and Therapy, Volume 19, 1-12. https://doi.org/10.2147/ott.s569536

Vancouver

Hu S, Wang Y, Tian G, Qiu Z. The Dual Role of SLC7A11 in Colorectal Cancer Ferroptosis: From Molecular Mechanisms to Therapeutic Opportunities. OncoTargets and Therapy. 2026;Volume 19:1-12. doi:10.2147/ott.s569536

BibTeX
@article{Hu2026,
  author = {Hu, Siyu and Wang, Yuting and Tian, Guangyu and Qiu, Zhiyuan},
  title = {The Dual Role of SLC7A11 in Colorectal Cancer Ferroptosis: From Molecular Mechanisms to Therapeutic Opportunities},
  journal = {OncoTargets and Therapy},
  year = {2026},
  volume = {Volume 19},
  pages = {1--12},
  doi = {10.2147/ott.s569536}
}
Kostenlos starten →